Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Journal of the National Comprehensive Cancer Network, Harborside Press, LLC, Vol. 20, No. 3.5 ( 2022-03-31), p. CLO22-051-
    Type of Medium: Online Resource
    ISSN: 1540-1405 , 1540-1413
    Language: Unknown
    Publisher: Harborside Press, LLC
    Publication Date: 2022
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 41, No. 16_suppl ( 2023-06-01), p. e23007-e23007
    Abstract: e23007 Background: Cancer research has rapidly evolved over the last few decades which has led to an improvement in patient care and outcomes. Dissemination of this research presented at meetings is essential to inform clinical practice. However, there continues to be a delay in the publication of data even after successful presentation of research as abstracts. In our study, we aim to determine abstract characteristics associated with successful peer-reviewed publication after presentation at the American Society of Clinical Oncology (ASCO) annual meeting for Breast and Gynecological malignancies. Methods: All oral abstracts (OA) & poster abstracts (PA) presented in the Breast & Gynecologic cancers categories from 2017/2018 ASCO annual meetings were included in the retrospective study. Manuscript publication was confirmed by searching PubMed using a data cut-off of December 2022. Publication characteristics like number of authors, time to publication (in months (mo)), study size, nature of results, impact factor, gender, H-index, citation of first author (FA) & last author (LA), NIH funding of LA were collected. Univariate logistic regression modeling was used to measure the association between publication status and select predictors. Results: 40/50 (80%) OA & 246/527 (46.6%) PA were published in PubMed indexed journals. Mean time to publication for OA was 17.41 mo & for PA was 19.52 mo. Mean IF for published OA was 28 & PA was 9.98. Of presented abstracts, 30/50 (60%) OA & 313/527 (59.39%) PA had positive results. Of the ones published, 23/40 (57.5%) of OA (p=0.72) & 190/246 (77.2%) of PA (p 〈 0.001) had positive findings. 250/527 (49.14%) PA & 17/50 (33.3%) of OA were presented by females. Of the published OA, 15/40 (37.5%) had female FA & 10/40 (25%) female LA. For published PA, FA females were 118/246 (47.9%) while LA females were 86/246 (34.9%). For published PA, median H-index for FA was 33 & LA was 68. 16/40 (40%) LA of published OA & 62/246 (25%) of published PA had NIH funding. Conclusions: Our study reveals that poster abstracts with positive findings are more likely to be published, implying publication bias in research. In addition, there is also higher likelihood of publication if last author is NIH funded. Our study highlights the need to address these factors to maximize the chances of publication of impactful research. [Table: see text]
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2023
    detail.hit.zdb_id: 2005181-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 82, No. 12_Supplement ( 2022-06-15), p. 31-31
    Abstract: Background: Murine tumor models show that cold stress increases tumor growth rate by norepinephrine release, altering the tumor microenvironment (TME). Tumor-bearing mice when housed at standard temperature of 22°Celsius (°C) exhibited a pro-tumorigenic TME (with fewer CD8+ T Cells and an increase in immunosuppressive cells) than mice housed at 30°C. The incidence of cancer has been shown to be higher in colder climates. Achievement of pathologic complete response (pCR) following neoadjuvant chemotherapy (NAC) for early stage breast cancer (BC) is associated with improved overall survival (OS) and disease specific survival (DSS). Based on these findings, we hypothesized that pCR would be increased while mortality would be decreased in BC patients (pts) living in warmer climates. Methods: A retrospective, population-based analysis was conducted utilizing the Surveillance, Epidemiology and End Results (SEER) from 1996-2017 and National Cancer Database (NCDB) from 2004-2018, and average annual temperature (AAT) data from the National Centers for Environmental Information. Cut-offs for AAT were obtained using the Youden’s index (for pCR) and maximum log-rank (for OS and DSS) methods. Associations between AAT and both pCR and OS/DSS were evaluated using logistic and Cox regression models, respectively, adjusting for confounders (age, race, education, insurance, BC subtype, treatment). Results: A total of 1,209,332 and 270,496 stage I-III BC pts in the US were analyzed using NCDB and SEER, respectively. In NCDB, 52.1% were hormone receptor (HR)+/HER2-, 8.6% triple negative (TNBC), 7.2% HR+/HER2+ and 3.1% HR-/HER2+ and 29% unknown. 37.7% received chemotherapy, 62.6% radiation and 94.3% surgery. 10.2% pts received NAC and 19.5% (19,021/97,669) achieved pCR. The AAT ranged from 44.7°Fahrenheit (°F) to 62.3°F with median 50.9°F. When adjusting for covariates, pts in regions with AAT & gt; 60.9°F, had a greater chance of achieving pCR compared to AAT & lt; 60.9°F with odds ratio (OR) 1.12 (95% CI 1.07-1.18), p & lt;0.001. This was consistent in the TNBC and HR-/HER2+ subgroups with OR 1.14 (95% CI 1.07-1.23) and 1.15 (95% CI 1.04-1.27), respectively. There was a 2% improvement in OS with every 5°F increment, HR 0.98 (95% CI 0.97-0.99), p & lt; 0.001. In SEER, 22.4% were HR+/HER2-, 4.4% TNBC, 4.0% HR+/HER2+, 1.8% HR-/HER2+ and 68.5% unknown. 43.4% received chemotherapy, 49.7% radiation and 94.2% surgery. The AAT ranged from 33.6°F to 67.3°F with median 57.4°F. There was a 3% improvement in OS [HR 0.97 (95% CI 0.968-0.977), p & lt; 0.001] and 2.5% improvement in DSS [HR 0.98 (95% CI 0.968-0.982), p & lt;0.001] with every 5°F increment. Conclusions: Higher environmental temperatures are associated with significant improvements in rate of pCR, OS and DSS in Stage I-III BC pts. Research focusing on underlying mechanisms and therapeutic strategies to abrogate this disparity is warranted. Citation Format: Ashish Gupta, Kristopher Attwood, Kush Gupta, Asha Gandhi, Stephen Edge, Kazuaki Takabe, Elizabeth Repasky, Shipra Gandhi. Favorable impact of higher environmental temperature on clinical outcomes in breast cancer - Does residence matter? A NCDB and SEER population-based study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 31.
    Type of Medium: Online Resource
    ISSN: 1538-7445
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2022
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    MDPI AG ; 2021
    In:  International Journal of Molecular Sciences Vol. 22, No. 21 ( 2021-11-02), p. 11878-
    In: International Journal of Molecular Sciences, MDPI AG, Vol. 22, No. 21 ( 2021-11-02), p. 11878-
    Abstract: Derangement of the phosphatidylinositol-3 kinase (PI3K) pathway is implicated in several subtypes of breast cancers. Mutation or upregulation of PI3K enhances cancer cells’ survival, proliferation, and ability to metastasize, making it an attractive molecular target for systemic therapy. PI3K has four isoforms, and several drugs targeting individual isoforms or pan-PI3K have been or are currently being investigated in clinical trials. However, the search for an effective PI3K inhibitor with a robust therapeutic effect and reasonable safety profile for breast cancer treatment remains elusive. This review focuses on the recently completed and ongoing clinical trials involving PI3K inhibitors as mono- or combination therapy in breast cancer. We review the salient findings of clinical trials, the therapeutic efficacy of PI3K inhibitors, and reported adverse effects leading to treatment discontinuation. Lastly, we discuss the challenges and potential opportunities associated with adopting PI3K inhibitors in the clinic.
    Type of Medium: Online Resource
    ISSN: 1422-0067
    Language: English
    Publisher: MDPI AG
    Publication Date: 2021
    detail.hit.zdb_id: 2019364-6
    SSG: 12
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    In: Blood, American Society of Hematology, Vol. 136, No. Supplement 1 ( 2020-11-5), p. 5-6
    Abstract: Introduction: Sickle cell disorders (SCD) is associated with progressive dysfunction of vital organs, including the cardiovascular system. While the development of pulmonary hypertension and left ventricular dysfunction have been previously studied, the burden of arrhythmias in SCD patients remains largely unknown. Thus, we aim to describe and analyze the prevalence and impact of arrhythmias in hospitalized adult patients with SCD and their impact in patient-oriented outcomes. Methods: We identified incident arrhythmias in patients with SCD in the National Inpatient Sample (NIS) database in 2 years (2016-2017), using ICD-10 codes. We compared major patient characteristics, outcomes, and economic impact between groups of SCD patients with and without documented arrhythmias. A logistic regression model was used to control for age, sex, race, admission type, hospital characteristics, and relevant comorbidities. To increase statistical robustness, propensity-score matching for age, sex, income, and comorbidities was used to match 1144 SCD patients with arrhythmia and 1144 patients without. Results: Among inpatients with SCD in the database, 5,930 of 174,450 patients with SCD had documented arrhythmias (3.4%). The arrhythmia group consisted mostly of patients' sickle cell disease (5,650; 95%), while 245 had sickle cell trait, and 35 were classified as having other sickle cell disorders. Individuals in the arrhythmia group were significantly older (mean age 41.3, SD 14.1) than those with no arrhythmia (mean age 31.5, SD 10.3). Further, arrhythmia group had higher prevalence of hypertension (44.2% vs 19.1%, p & lt;0.001), congestive heart failure (25.8% vs 4.1%, p & lt;0.001), chronic kidney disease (24.0% vs 5.6%, p & lt;0.001), valvular heart disease (9.3% vs 1.5%, p & lt;0.001), myocardial infarction (4.1% vs 1.25%, p & lt;0.001), type 2 diabetes mellitus (3.5% vs 1.7%, p & lt;0.001), and pulmonary hypertension (3.5% vs 1.2%, p & lt;0.001). When looking at major outcomes, after adjusting for confounders, arrhythmias were positively associated with all cause in-hospital mortality with an adjusted OR of 53.6 (95% CI 44.3, 65.1). After propensity-matching (Table 1), the arrhythmia group had a higher rate of all-cause in-hospital mortality (6.12% vs 0.35%, p & lt;0.001), higher median length of stay (6.8 days vs 5.8 days, p & lt;0.001), and mean total hospital charges ($13,441 vs $10,255, p & lt;0.001). There was no statistically significant difference in the rate of stroke between both groups. Conclusions: The presence of arrhythmias in patients with SCD was associated with markedly increased all cause in-hospital mortality, even after adjusting for confounders via logistic regression and propensity-score matching analyses. Despite a relatively low overall prevalence of 3.4% among this large inpatient cohort, this data suggests that arrhythmias may confer an important excess disease burden in SCD patients, including higher mortality. Intuitively, arrythmias confer higher mortality in patients with chronic disorders and multiple cardiovascular risks, whether this is specific to SCD deserves further study. Also, studies are needed to better understand the occurrence particularly in relation to active vaso-occlusive crisis and to evaluate whether SCD individuals with arrhythmias could potentially benefit from more intensive monitoring and/or better cardiovascular disease control. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2020
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    Online Resource
    Online Resource
    OMICS Publishing Group ; 2015
    In:  Journal of Hematology & Thromboembolic Diseases Vol. 03, No. 01 ( 2015)
    In: Journal of Hematology & Thromboembolic Diseases, OMICS Publishing Group, Vol. 03, No. 01 ( 2015)
    Type of Medium: Online Resource
    ISSN: 2329-8790
    Language: Unknown
    Publisher: OMICS Publishing Group
    Publication Date: 2015
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    In: Cancers, MDPI AG, Vol. 15, No. 17 ( 2023-08-25), p. 4264-
    Abstract: Background: The interaction between HER2-low expression, oncotype recurrence score (RS), and their influence on the prognosis of HR+/HER2- breast cancer (BC) is not very well studied. Methods: We conducted a retrospective cohort study of patients diagnosed with resectable HER2-low and HER2-zero BC from the National Cancer Database. The primary outcome was overall survival (OS), and the association of RS with the clinical outcomes in HR+/HER2- BC was analyzed as an exploratory endpoint. Results: The distribution of RS was comparable between HER2-low and HER2-zero groups; however, the RSs of HER2-low tumors were more likely to be 16–25. Women with HER2-low tumors had longer 5-year OS than women with HER2-zero tumors in the HR-negative (84.3% vs. 83.9%; p 〈 0.001, HR: 0.87 (0.84–0.90), p 〈 0.001) but not in the HR-positive group (94.0% vs. 94.0%; p = 0.38, HR: 0.97 (0.95–0.99), p = 0.01). The survival advantage was observed in patients who received adjuvant/neoadjuvant chemotherapy (p-interaction (chemo vs. no chemo) 〈 0.001). Among those who received adjuvant chemotherapy in the group with higher RSs (26–100), those with HER2-low BC had higher 5-year OS than HER2-zero BC. Conclusions: Resectable HER2-low BC had a better prognosis than HER2-zero BC. Among those who received adjuvant chemotherapy in the higher oncotype RS group, those with HER2-low tumors had better survival.
    Type of Medium: Online Resource
    ISSN: 2072-6694
    Language: English
    Publisher: MDPI AG
    Publication Date: 2023
    detail.hit.zdb_id: 2527080-1
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Online Resource
    Online Resource
    American Society of Clinical Oncology (ASCO) ; 2023
    In:  Journal of Clinical Oncology Vol. 41, No. 16_suppl ( 2023-06-01), p. e12514-e12514
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 41, No. 16_suppl ( 2023-06-01), p. e12514-e12514
    Abstract: e12514 Background: Breast cancer (BC) is a heterogenous disease with several different subtypes and histological variants (HV) with varied levels of aggressiveness, survival, and response to treatments. National Comprehensive Cancer Network (NCCN) guidelines do not recommend chemotherapy (CT) for some of these HR+ HVs. Given the rarity of these HVs, there is a paucity of data regarding optimal management. We aim to study the benefit of CT in these rare HVs of BC. Methods: We queried the National Cancer Database for stage I, II, III BC patients (pts) with mucinous, papillary, tubular, and medullary HVs from the years 2010-2019. Pts 〉 18 years (yrs) treated with surgery were included and the population was divided into two cohorts based on the receipt of CT (CT and no CT). Cox Proportional Hazards regression was used to adjust for covariates associated with overall survival (OS) including age, race, gender, income, stage, grade, insurance status, education, comorbidities, and treatments received. Results: In the mucinous histology, out of 16,162 pts, 10% (n = 1,620) received CT. Pts who received CT were younger (54 vs 68 yrs p 〈 0.001). When stratified by T and N-stage, 5-yr (OS) was higher in the CT compared to the no CT cohort, with higher survival differences observed in higher T (T1: 96% vs 90%, T2: 94% vs 84%, T3: 90% vs 74%, T4: 80% vs 50%) and N-stages (Node negative (N0): 95% vs 88%, Node positive (N+): 88% vs 72%) (all p 〈 0.001). Although, pts who received CT had better OS on univariate (UV) analysis (no CT: HR 2.04, 95% CI = 1.71-2.43, p 〈 0.001), this difference was not observed on multivariate (MV) analysis (no CT: HR 1.1, 95% CI = 0.9-1.3, p = 0.28). In the papillary and tubular histology, 12% (280/2324) and 4.3% (211/4980) pts received CT respectively. No significant survival benefit with CT was observed in both papillary and tubular histology in any T or N stages (overall 5-yr OS: Papillary 88% vs 85%, p = 0.2; Tubular 93% vs 94%, p = 0.8). The administration of CT was associated with poor outcomes in both (MV HR: Papillary 1.76, 95% CI = 1.2-2.6, p 〈 0.001; Tubular 1.87, 95% CI = 1.13-3.1, p 〈 0.001). In the medullary histology, out of 472 pts, 81% (n = 382) received CT. Those who received CT were younger (51 vs 65 yrs) and node positive (18.5% vs 4%) (both p 〈 0.001). The OS was higher in CT group compared to no CT (3-yr OS: 97% vs 94%, 5-yr OS: 96% vs 85%, MV HR for CT: 0.34, 95% CI = 0.17-0.67, all p 〈 0.001). The observed survival difference in CT vs no CT groups was irrespective of the T- and N-stages (5-yr OS:- T1: 100% vs 91%, T2: 95% vs 76%, N0: 97% vs 88%, N+: 95% vs 50%, all p 〈 0.001). Conclusions: As consistent with the NCCN guidelines, in this large retrospective study, we did not observe any benefit with CT among mucinous, papillary and tubular histology. However, in medullary histology, CT has OS benefit in HR+ BC subtype. Multicenter clinical trials would be beneficial to assess the impact of CT in HVs and to reassess guidelines.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2023
    detail.hit.zdb_id: 2005181-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Online Resource
    Online Resource
    American Society of Clinical Oncology (ASCO) ; 2017
    In:  Journal of Clinical Oncology Vol. 35, No. 15_suppl ( 2017-05-20), p. e14590-e14590
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 35, No. 15_suppl ( 2017-05-20), p. e14590-e14590
    Abstract: e14590 Background: The benefit of CPI is limited to a subgroup of patients. Significant toxicity and financial burden make it imperative to identify biomarkers predictive of clinical benefit. We aimed to analyze if immune related adverse events (irAE), laboratory parameters (besides PD-L1 status), prior chemotherapy and concomitant medication use could predict response to CPI. Methods: 216 consecutive patients treated at RPCI with single/multiple CPI from 2011 to 2016 were identified. Demographics, irAE (CTCAE v4.03), concomitant medication use, response (RECIST v1.1) and laboratory parameters were recorded. Progression free (PFS) and overall survival (OS) were calculated. Clinical benefit (responder) was defined as objective response or stable disease with PFS ≥ 6 months. Statistical analysis was performed using SAS v9.4. Results: 185/216 patients (86%) had clinical outcomes with first CPI available (55.7% melanoma, 28.1% lung, 10.8% kidney, 3.8% bladder, 1.6% others), 14% died before disease assessment. Median age was 61 years; 64% were males. 31% were responders (R); 69% non-responders (NR). Median PFS and OS for R were not reached and for NR were 4.7/7 months (p 〈 0.001). 26% R developed rash vs. 12% NR (p = 0.02). irAE diarrhea was associated with better OS (p = 0.03); rash with better PFS (p = 0.007) and OS (p = 0.05). Concomitant beta-blocker/NSAID use was noted in 35%/28% R vs 20%/12% NR (p = 0.04; p = 0.01). Higher median absolute eosinophil (AEC) and absolute lymphocyte count (ALC) were noted in R (400 and 2000/µl in R vs. 300 and 1600/µl in NR; p = 0.008 and 0.024). NR were noted to have a higher median lactate dehydrogenase (LDH) of 565 vs. 503 (p 〈 0.001). AEC 〉 100/µl and ALC 〉 1000/ µl were associated with better OS (P = 0.03; P = 0.001). Absolute neutrophil count (ANC) 〉 7500/µl and leucocyte count 〉 8750/ µl were associated with inferior PFS (p = 0.005; P = 0.02) and OS (p = 0.002; p = 0.03). Pre-CPI chemotherapy did not correlate with response to CPI. Conclusions: Among irAE, diarrhea and rash predicted improved outcomes. Eosinophilia, lymphocytosis, neutrophilia, leukocytosis and LDH could serve as potential prognostic biomarkers to CPI. Prospective studies are warranted to validate these findings.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2017
    detail.hit.zdb_id: 2005181-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Online Resource
    Online Resource
    American Society of Clinical Oncology (ASCO) ; 2021
    In:  Journal of Clinical Oncology Vol. 39, No. 15_suppl ( 2021-05-20), p. e12546-e12546
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 39, No. 15_suppl ( 2021-05-20), p. e12546-e12546
    Abstract: e12546 Background: Norepinephrine released during cold stress by housing 4T1 TNBC mice at 22°C increases tumor growth with a pro-tumorigenic TME [lower CD8 + T-cells, higher myeloid derived suppressor cells (MDSC) and regulatory T-cells (Treg)] compared with mice housed at 30°C. Norepinephrine activates thermogenesis in adipose tissue. Worse survival has been reported among females with malignancies l iving in cold versus warm climate. These findings led us to hypothesize that TNBC with enhanced thermogenesis is associated with worse outcome and unfavorable TME. Methods: mRNA expression data for 298 and 143 TNBC patients was accessed from METABRIC and GSE96058 breast cancer cohorts, respectively. TNBC were classified into “high” (top tertile) and “low” thermogenesis (bottom two-third) using Gene Set Variation Analysis (GSVA) with KEGG thermogenesis pathway. Computer algorithms xCell and Gene Set Enrichment Analysis (GSEA) were used. Interferon (IFN)-γ signature was calculated using GSVA. Gene expression data was used to quantify adipocytes, angiogenesis, chemokines and cytolytic activity (CYT). R software was used for analysis. False discovery rate (FDR) 〈 0.25 for GSEA and p 〈 0.05 was considered statistically significant. Results: High-thermogenesis TNBC was associated with a worse median disease specific survival 14.7 years vs. not reached [HR 1.49 (95% CI 1.02-2.18)], p 〈 0.05 in METABRIC and a trend towards worse overall survival in both METABRIC and GSE96058. Higher fraction of adipocytes (p 〈 0.001) and angiogenesis markers including CD31, vWF, Vascular endothelial cadherin, claudin 5, JAM2 and sphingosine-1-phosphate related gene S1PR1 (p 〈 0.01) were observed explaining the worse survival in high-thermogenesis TNBC. This group was significantly enriched in fatty acid metabolism and adipogenesis pathways (FDR 〈 0.25) on GSEA. On the other hand, low-thermogenesis TNBC was enriched in mitotic spindle, E2F targets, G2M checkpoint, MYC targets consistent with higher Ki67 (p 〈 0.05) in this group; and also in IFN-α and IFN-γ response (FDR 〈 0.25). High-thermogenesis TNBC was associated with lower IFN-γ and granzyme B expression (p 〈 0.05). Favorable cytotoxic-T cell attracting chemokines CCL5, CXCL9, CXCL10 and CXCL11 were lower; MDSC-, Treg-favoring chemokine CXCL12 was higher (p 〈 0.05). There were lower M1 and more M2 macrophages (p 〈 0.001) with lower CYT. There was higher expression of dual-specificity phosphatase-1 ( DUSP1)(p 〈 0.05), which is upregulated following glucocorticoid receptor activation. Conclusions: We investigated the clinical relevance of preclinical findings and observed that high-thermogenesis TNBC is associated with worse survival and unfavorable TME. Further research is warranted to validate if high thermogenesis could reflect tumors under thermal stress and develop novel strategies to abrogate stress and improve outcomes.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2021
    detail.hit.zdb_id: 2005181-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages